Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fumaderm in cutaneous lupus erythematosus
2010-023645-29Phase 2Completed
- Sponsor
- Universitätsklinikum Münster
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Fumaderm in cutaneous lupus erythematosus (CLE), sponsored by Universitätsklinikum Münster. Primary endpoint: Responder rate at week 24. Started Jan 2011; status: completed.
02
Drugs
Fumaderm
03
Conditions
cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on 2010-023645-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023645-29.